Wellington Management Group’s Aligos Therapeutics ALGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-18,846
Closed -$1.01M 2065
2022
Q1
$1.01M Sell
18,846
-123,633
-87% -$9.9M ﹤0.01% 1732
2021
Q4
$42.3M Sell
142,479
-10,696
-7% -$3.9M 0.01% 879
2021
Q3
$59.4M Sell
153,175
-13,848
-8% -$5.48M 0.01% 765
2021
Q2
$85.1M Buy
167,023
+7,051
+4% +$4.49M 0.01% 675
2021
Q1
$90.8M Buy
159,972
+2,868
+2% +$1.91M 0.02% 640
2020
Q4
$107M Buy
+157,104
New +$76.5M 0.02% 574

Other funds holding ALGS

Wellington Management Group's ALGS Position: Q2 2022 in Review

Wellington Management Group sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 18,846 shares — an estimated $1.01M sold.

Wellington Management Group first reported a position in ALGS in Q4 2020 and held it in 6 quarters. The position peaked at $107M in Q4 2020. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

  • Wellington Management Group reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Wellington Management Group sold 18,846 Aligos Therapeutics shares in Q2 2022, an estimated $1.01M.
  • Wellington Management Group first reported a position in Aligos Therapeutics in Q4 2020 and held it in 6 quarters.
  • Wellington Management Group's Aligos Therapeutics position peaked at $107M in Q4 2020.
  • 59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on Wellington Management Group's 13F filing for Q2 2022, filed 15 Aug 2022.